New hope for lung cancer patients with stubborn mutation

NCT ID NCT06868485

Recruiting now Disease control Sponsor: Wayshine Biopharm, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tests an experimental oral drug called WSD0922-FU in 40 adults with advanced non-small cell lung cancer that has a specific mutation (C797S) and has stopped responding to the standard treatment osimertinib. The main goal is to see if the drug can shrink tumors. It is an early-stage trial, so success is not guaranteed.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: WSD0922-FU (an oral drug targeting a specific lung cancer mutation)
What this could lead to: If it works, this could offer a new treatment option for people with a specific type of lung cancer that has stopped responding to current therapy.
What could go wrong: This is an early Phase 2 trial with only 40 participants, so results may not apply to everyone. The drug may not shrink tumors or could cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-SMALL CELL LUNG CANCER

Contacts and locations

Locations

CHU Bordeaux - Centre Francois Magendie
RECRUITING

Pessac, New Aquitaine, 33604, France
CHU Toulon - Hopital Sainte Musse
RECRUITING

Toulon, Var, 83100, France
Centre Francois Baclesse
RECRUITING

Caen, Normandy, 14000, France
Centre Hospitalier Universitaire (CHU) de Rennes - Hopital de Pontchaillou
RECRUITING

Rennes, Ille-et-Vilaine, 35000, France
Centre Hospitalier Universitaire CHU De Limoges
RECRUITING

Limoges, New Aquitaine, 87042, France
Cleveland Clinic
RECRUITING

Cleveland, Ohio, 44195, United States
Cleveland Clinic Weston Hospital
RECRUITING

Weston, Florida, 33331, United States
FOMAT Oncology
RECRUITING

Oxnard, California, 93030, United States
Fujian Provincial Cancer Hospital
RECRUITING

Fuzhou, Fujian, 350014, China
Hackensack Meridian Health-Southern Ocean Medical Center
RECRUITING

Manahawkin, New Jersey, 08050, United States
Karmanos Cancer Institute
RECRUITING

Detroit, Michigan, 48201, United States
Shanghai East hospital
RECRUITING

Shanghai, Shanghai Municipality, 200120, China
Shanghai Pulmonary Hospital
RECRUITING

Shanghai, Shanghai Municipality, 200433, China
Tianjin Medical University Cancer Institute and Hospital
RECRUITING

Tianjin, Tianjin Municipality, 300202, China
TxO Central/South, Texas Oncology -Central/South Texas
RECRUITING

Austin, Texas, 78745, United States
UPMC Hillman Cancer Center
RECRUITING

Pittsburgh, Pennsylvania, 15235, United States
Virginia Cancer Specialists
RECRUITING

Fairfax, Virginia, 22031, United States
Wuhan Union Hospital
RECRUITING

Wuhan, Hubei, 430022, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.